Results 1 to 10 of about 4,397 (69)

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial [PDF]

Nature Medicine
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, Sylvia Hartl, Patrick M. Forde, Maximilian J. Hochmair, Mark M. Awad, Michael Thomas, Glenwood Goss, Paul Wheatley‐Price, Frances A. Shepherd, Marie Florescu, Parneet Cheema, Quincy S. Chu, Sang‐We Kim, Daniel Morgensztern, Melissa L. Johnson, Sophie Cousin, Dong‐Wan Kim, Mor Moskovitz, David Vicente, Boaz E. Aronson, Rosalind Hobson, Helen J. Ambrose, Sajan Khosla, Avinash Reddy, Deanna L. Russell, Mohamed Reda Keddar, James Conway, J. Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J. Jewsbury, Sonia Iyer, Simon T. Barry, Jan Cosaert, John V. Heymach   +37 more
openalex   +3 more sources

700 A phase II trial of MOnaliZumab plus durvAlumab plus platinum-based chemotheRapy for first-line treatment of extensive stage small cell lung cancer (MOZART): A Hoosier Cancer Research Network study [PDF]

, 2023
Hirva Mamdani, Seongho Kim, Jie Chi, Deleted Author ID, Deleted Author ID, Shadia I. Jalal   +5 more
openalex   +1 more source

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003) [PDF]

, 2022
Hidenobu Ishii, Koichi Azuma, Takayuki Shimose, Hiroshige Yoshioka, Takayasu Kurata, Naoki Shingu, Masaki Okamoto, Yosuke Kawashima, Isamu Okamoto   +8 more
openalex   +1 more source

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report [PDF]

, 2020
Ana Rita Lopes, Alessandro Russo, Andrew Y. Li, Michael G. McCusker, Jeffrey Myles Kroopnick, Katherine A. Scilla, Ranee Mehra, Christian Rolfo   +7 more
openalex   +1 more source

1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)? [PDF]

, 2020
Constanza Linossi, Ionut-Gabriel Funingana, Michele Petruzzelli, Bruno de Paula, Maria O’Donovan, Manconi Andrea, Stephane Hewitt, Adenike Williams, Nicola Grehan, Aisling M. Redmond, E.C. Smyth, Richard D. Baird, Edmund Godfrey, M Di Pietro, Iris Faull, Simon J. Dovedi, Rebecca C. Fitzgerald, Simon Pacey   +17 more
openalex   +1 more source

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial [PDF]

, 2022
Peey‐Sei Kok, Patrick M. Forde, Brett Hughes, Zhuoxin Sun, Chris Brown, Suresh S. Ramalingam, Alistair Cook, W. Joost Lesterhuis, Sonia Yip, Kenneth J. O’Byrne, Nick Pavlakis, Julie R. Brahmer, Valsamo Anagnostou, Kate Ford, Karen Fitzpatrick, Alison Bricker, Michelle M. Cummins, Martin R. Stockler, Anna K. Nowak   +18 more
openalex   +1 more source

The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis [PDF]

, 2023
Zhenyi Yang, Wen Zhong, Yixuan Luo, Chunli Wu   +3 more
openalex   +1 more source

P28.01 Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC [PDF]

, 2021
Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Andrew Barnabas Wong, Yvonne Ang, Yugarajah Asokumaran, Jia Li Low, M. Lee, Joan Choo, Gloria Chan, Adrian Kee, Sen Hee Tay, Boon Cher Goh, Ross A. Soo   +13 more
openalex   +1 more source

Supplementary Figures S1-S9 from Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

, 2023
Charu Aggarwal, Nabil F. Saba, Alain P. Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T. Esser, Lily Cheng, Sonia Agrawal, Emily C. Jennings, Nicholas M. Durham, Karl Fraser, Delphine Lissa, Maozhen Gong, Natalia Ceaicovscaia, Amaya Gascó Hernández, Rakesh Kumar   +19 more
openalex   +1 more source

Supplementary Figure S6 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial

, 2023
Shuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, Vinita Takiar, Maria Lehn, Ilaina Monroe, Sarah Palackdharry, Nicky Kurtzweil, Roman Jandarov, Nusrat Harun, Trisha M. Wise‐Draper   +10 more
openalex   +1 more source